menu
    • menu
    [{"orgOrder":0,"company":"Aevisbio","sponsor":"KB investment","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series A Financing","leadProduct":"3,6\u2019-dithiopomalidomide","moa":"TNF-alpha receptor","graph1":"Neurology","graph2":"IND Enabling","graph3":"Aevisbio","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aevisbio \/ KB investment","highestDevelopmentStatusID":"5","companyTruncated":"Aevisbio \/ KB investment"}]

    Find Clinical Drug Pipeline Developments & Deals by Aevisbio

    Menu

    Aevisbio

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Aevisbio

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed

                            Aevisbio

                            U.S.A arrow
                            APGA Annual Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 3,6’-dithiopomalidomide

                            Therapeutic Area : Neurology

                            Study Phase : IND Enabling

                            Sponsor : KB investment

                            Deal Size : $10.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            AevisBio Publishes Data with NIH Demonstrating Novel Immunomodulatory Imide Drug Reduces Neuroinflammation and...

                            Details : The proceeds of the financing will be used to evaluate the safety profile of AEV103 and other TPD lead drug candidates as potential treatments for neurodegenerative disorders. AEV103 is a next generation immunomodulatory imide drug that binds strongly to...

                            Product Name : AEV103

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            February 03, 2022

                            Lead Product(s) : 3,6’-dithiopomalidomide

                            Therapeutic Area : Neurology

                            Highest Development Status : IND Enabling

                            Sponsor : KB investment

                            Deal Size : $10.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth